LEGNLegend Biotech Corporation
21.82USD-3.45%Mkt Cap: 4.24B $P/E: —3d ago
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the Unit…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap4.24B $
Enterprise Value3.29B $
Revenue (TTM)1.27B $
Gross Profit620.80M $
Net Income (TTM)-296.80M $
Revenue/Share6.859 USD
Last Price21.82 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees3.2K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)19.69
PEG—
EV/EBITDA-75.99
EV/Revenue2.59
P/S3.25
P/B3.23
EPS (TTM)-0.47
EPS (Forward)1.08
52W Range
16.2426% of range38.12
52W High38.12 USD
52W Low16.24 USD
Profitability
Gross Margin60.34%
Oper. Margin14.89%
EBITDA Margin-3.40%
Profit Margin-28.85%
ROE-29.62%
ROA-17.12%
Growth
Revenue Growth51.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-100.20M $
CapEx (TTM)28.60M $
FCF Margin1.21%
FCF Yield0.36%
Net Debt-686.40M $
Net Debt/EBITDA15.86
Balance Sheet
Debt/Equity0.41
Current Ratio3.04
Quick Ratio2.39
Book Value/Sh6.575 USD
Cash/Share5.158 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)49.25 USD
Upside (mean)+125.7%
Target Range24.00 USD – 78.00 USD
$24.00+125.7% to mean$78.00
# Analysts15
Ownership
Shares Out.194.49M
Float87.29M
Insiders1.25%
Institutions56.86%
Short Interest
Short Ratio7.3d
Short % Float22.31%
Short % Out.9.36%
Shares Short18.11M
Short (prev mo.)13.11M
Technical
SMA 5025.12 (-13.2%)
SMA 20023.71 (-8.0%)
Beta0.39
S&P 52W Chg18.16%
Avg Vol (30d)2.44M
Avg Vol (10d)2.71M
Technical Indicators
RSI (14)49.2
MACD-0.8765
MACD Signal-1.4433
MACD Hist.+0.5668
BB Upper23.22 USD
BB Middle20.33 USD
BB Lower17.44 USD
BB Width28.42%
ATR (14)1.235 USD
Vol Ratio (20d)0.52x